Literature DB >> 17670847

Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus.

S Barath1, M Aleksza, T Tarr, S Sipka, G Szegedi, E Kiss.   

Abstract

Abnormalities of regulatory T cells may play an important role in the loss of self-tolerance, which is a major characteristic of lupus. The objective of this study was to determine the ratio and the number of natural CD4+CD25highFoxp3+ and inducible CD4+IL-10+ regulatory T cells in lupus patients and to search correlation with disease activity. Seventy-two Hungarian lupus patients were enrolled in the study. Fourty-one age- and sex matched healthy donors served as controls. Flow cytometry was used for the quantification of CD4+CD25high Foxp3+ (nTreg) and CD4+IL-10+ (iTreg) cells. The ratio (3.06 +/- 1.45%) and the number (0.019 +/- 0.012 x 10(9)/L) of nTreg cells decreased in lupus significantly (P < 0.001 in both) as compared to normal controls (4.26 +/- 1.01% and 0.039 +/- 0.017 x 10(9)/L). The ratio of iTreg cells were significantly higher in patients than in controls (20.92 +/- 14.02% versus 15.49 +/- 11.65%, P < 0.03), but the number of these cell type did not differ in significant manner (0.314 +/- 0.236 x 10(9)/L versus 0.259 +/- 0.183 x 10(9)/L). The 19 active patients were characterised by significantly higher disease activity index (SLEDAI 8.63 +/- 2.95 versus 1.74 +/- 1.68, P < 0.001) and anti-DNA concentration (117.85 +/- 145.89 versus 37.36 +/- 68.85 IU/mL, P = 0.001) as compered to the 52 inactive patients. Furthermore, active patients required higher dose of methylprednisolon than inactive ones (14.8 +/- 10.6 versus 4.8 +/- 3.4 mg/day, P < 0.001). However, we did not find statistical significant difference in the number and ratio of the examined cell populations regarding to disease activity. Altered ratio and number of both natural and inducible regulatory T cells may play a role in the pathogenesis of lupus. There are small but appreciable difference in the number of regulatory T cells between inactive patients and healthy controls. It suggests that immunoregulatory deficiencies are present in the inactive stage of the disease also.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670847     DOI: 10.1177/0961203307080226

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  28 in total

1.  Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus.

Authors:  Adriana Elizabeth Monsiváis-Urenda; Lourdes Baranda; Crisol Alvarez-Quiroga; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2010-12-29       Impact factor: 8.317

Review 2.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

3.  Malignant lymphomas and autoimmunity-a single center experience from Hungary.

Authors:  László Váróczy; Edit Páyer; Zsuzsanna Kádár; Lajos Gergely; Zsófia Miltényi; Ferenc Magyari; Péter Szodoray; Arpád Illés
Journal:  Clin Rheumatol       Date:  2011-07-07       Impact factor: 2.980

Review 4.  T cells and IL-17 in lupus nephritis.

Authors:  Tomohiro Koga; Kunihiro Ichinose; George C Tsokos
Journal:  Clin Immunol       Date:  2016-04-21       Impact factor: 3.969

5.  Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  Mojtaba Habibagahi; Zahra Habibagahi; Mansooreh Jaberipour; Amir Aghdashi
Journal:  Rheumatol Int       Date:  2010-04-02       Impact factor: 2.631

Review 6.  Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review.

Authors:  Britt Nakken; Edit Bodolay; Peter Szodoray
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

7.  Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome.

Authors:  P Szodoray; G Papp; I F Horvath; S Barath; S Sipka; B Nakken; M Zeher
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

Review 8.  T cells as a therapeutic target in SLE.

Authors:  D Comte; M P Karampetsou; G C Tsokos
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

9.  NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Eliana A G Reis; Daniel A Athanazio; Isabella Lima; Natália Oliveira e Silva; Jorge Clarencio S Andrade; Ronden N Jesus; Lúcio M Barbosa; Mitermayer G Reis; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2008-09-28       Impact factor: 2.631

Review 10.  From autoinflammation to autoimmunity: old and recent findings.

Authors:  Francesco Caso; Luisa Costa; Valeria Nucera; Giuseppe Barilaro; Ignazio Francesco Masala; Rossella Talotta; Paolo Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Clin Rheumatol       Date:  2018-07-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.